These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 7483151)

  • 1. [Advanced prostatic carcinoma--which hormone therapy when?].
    Studer UE
    Urologe A; 1995 Sep; 34(5):361-6. PubMed ID: 7483151
    [No Abstract]   [Full Text] [Related]  

  • 2. [Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma].
    Bruchovsky N; Goldenberg SL; Rennie PS; Gleave M
    Urologe A; 1995 Sep; 34(5):389-92. PubMed ID: 7483155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Renaissance of estrogen therapy in advanced prostate carcinoma?].
    Smith PH; Robinson MR
    Urologe A; 1995 Sep; 34(5):393-7. PubMed ID: 7483156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma].
    DeAntoni E; Crawford ED
    Urologe A; 1995 Sep; 34(5):382-8. PubMed ID: 7483154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical protocols in treatment of prostatic carcinoma in Europe. The role of EORTC and other organizations].
    Newling DW
    Urologe A; 1995 Sep; 34(5):374-81. PubMed ID: 7483153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maximal androgen blockade for advanced prostate cancer.
    Klotz L
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):331-40. PubMed ID: 18471790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Intramuscular depot estrogens (Estradurin) in treatment of patients with prostate carcinoma. Historical aspects, mechanism of action, results and current clinical status].
    Stege R; Carlström K; Hedlund PO; Pousette A; von Schoultz B; Henriksson P
    Urologe A; 1995 Sep; 34(5):398-403. PubMed ID: 7483157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Choice of first-line treatment for metastatic prostate cancer.
    Prescrire Int; 2013 Feb; 22(135):51. PubMed ID: 23444511
    [No Abstract]   [Full Text] [Related]  

  • 9. Study changes how physicians treat metastatic prostate cancer: intermittent hormone therapy not as effective as continuous hormone therapy, authors say.
    Printz C
    Cancer; 2013 Sep; 119(17):3103-4. PubMed ID: 24037668
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of delayed maximal androgen blockade therapy for patients with advanced prostate cancer who fail to respond to initial androgen deprivation monotherapy.
    Takayanagi A; Masumori N; Hashimoto J; Kyoda Y; Yanase M; Tsukamoto T
    Jpn J Clin Oncol; 2010 Dec; 40(12):1154-8. PubMed ID: 20647233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment options in hormone resistant prostate cancer.
    De Mulder PH; Schalken JA; Sternberg CN
    Ann Oncol; 2002; 13 Suppl 4():95-102. PubMed ID: 12401673
    [No Abstract]   [Full Text] [Related]  

  • 12. Words of wisdom: Re: High-risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen blockade: results of a phase III randomized study [abstract 3].
    Bolla M
    Eur Urol; 2013 Sep; 64(3):513. PubMed ID: 23915463
    [No Abstract]   [Full Text] [Related]  

  • 13. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup.
    Garzotto M; Wajsman Z
    J Urol; 1998 Mar; 159(3):950-4; discussion 954-5. PubMed ID: 9474190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormonal treatment of advanced disease: some newer aspects.
    Griffiths K; Eaton CL; Harper ME; Turkes A; Peeling WB
    Semin Oncol; 1994 Oct; 21(5):672-87. PubMed ID: 7939755
    [No Abstract]   [Full Text] [Related]  

  • 15. [Hormone therapy of locally advanced and metastatic prostate carcinoma].
    Rübben H
    Praxis (Bern 1994); 2001 Sep; 90(38):1641-4. PubMed ID: 11675917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is hormone ablation still the right choice for advanced prostate cancer?
    Fitzpatrick JM
    BJU Int; 2007 Jul; 100 Suppl 2():36-9. PubMed ID: 17594357
    [No Abstract]   [Full Text] [Related]  

  • 17. Biased hormonal therapy duration analysis makes results uninterpretable.
    Tangen CM; Goldman BH; Swanson GP; Thompson IM
    J Clin Oncol; 2009 Nov; 27(33):e203; author reply e204. PubMed ID: 19786655
    [No Abstract]   [Full Text] [Related]  

  • 18. [Current strategies of intermittent hormone therapy in prostate cancer].
    Kaprin AD; Pavlov AIu; Ivanov SA; Gafanov RA
    Vopr Onkol; 2011; 57(2):260-4. PubMed ID: 21809677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer: management of advanced disease.
    Droz JP; Fléchon A; Terret C
    Ann Oncol; 2002; 13 Suppl 4():89-94. PubMed ID: 12401672
    [No Abstract]   [Full Text] [Related]  

  • 20. Adjuvant treatment to radiation: combined hormone therapy and external radiotherapy for locally advanced prostate cancer.
    Bolla M; Descotes JL; Artignan X; Fourneret P
    BJU Int; 2007 Jul; 100 Suppl 2():44-7. PubMed ID: 17594359
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.